journal article·2024-12-31Open access

HBOC alleviated tumour hypoxia during radiotherapy more intensely in large solid tumours than regular ones

Yingcan Xu, Kehui Zhu, Jiakang Wu, Shifan Zheng, Rui Zhong, Wentao Zhou, Ye Cao, Jiaxin Liu, Hong Wang

Abstract

Radiotherapy (RT) is a highly valuable method in cancer therapy, but its therapeutic efficacy is limited by its side effects and tumour radiation resistance. The resistance is mainly induced by hypoxia in the tumour microenvironment (TME). As a nano-oxygen carrier, Haemoglobin-based oxygen carriers (HBOCs) administration is a promising strategy to alleviate tumour hypoxia which may remodel TME to ameliorate radiation resistance and enable RT more effective. In this study, we administered fractionated RT combined with HBOC to treat Miapaca-2 cell and Hela cell xenografts on nude mice. The study found that HBOC relieved hypoxic environment and down-regulate expression of hypoxia-inducible factor-1α (Hif-1α) both in regular (100 mm3) and large (360/400 mm3) tumours. The proliferation and metastasis of tumour tissue also decreased after HBOC application. Nevertheless, in vivo RT combined with HBOC performed more effectively to suppress tumour growth in large tumours than in regular tumours. This is due to more severe hypoxic regions exist in the large solid tumours compared to the regular counterparts, and HBOC administration may be more effective in alleviating hypoxia in large tumours. Thus, HBOC sensitization therapy is more suitable for large solid tumours.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer, Hypoxia, and Metabolism · Radiation Therapy and Dosimetry · Hemoglobin structure and function

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Peking Union Medical College, Chengdu, China

Funding

Sichuan Provincial Department of Science and Technology · Sichuan Cancer Hospital · CAMS Innovation Fund for Medical Sciences

References (41)

Show source-provided references
1. Lang JY. Retrospect, thinking and prospect of radiotherapy in China in the past 30 years. Cancer Prev Treat. 2017;30(1):1–4 + 6.
2. 10.18632/oncotarget.51210.18632/oncotarget.512 ↗
3. 10.3390/cancers1101011210.3390/cancers11010112 ↗
4. 10.1016/j.canlet.2012.11.01910.1016/j.canlet.2012.11.019 ↗
5. 10.1038/nrc395810.1038/nrc3958 ↗
6. 10.1038/nrc136710.1038/nrc1367 ↗
7. 10.1200/JCO.2007.12.787810.1200/JCO.2007.12.7878 ↗
8. 10.1021/acs.nanolett.1c0122010.1021/acs.nanolett.1c01220 ↗
9. 10.1039/c9sc06337d10.1039/c9sc06337d ↗
10. 10.1007/BF0118750010.1007/BF01187500 ↗
11. 10.1213/ANE.000000000000395710.1213/ANE.0000000000003957 ↗
12. 10.1517/14712598.1.5.83110.1517/14712598.1.5.831 ↗
13. 10.1007/s00066-005-1418-310.1007/s00066-005-1418-3 ↗
14. 10.1007/s00280-015-2897-210.1007/s00280-015-2897-2 ↗
15. 10.1371/journal.pcbi.100815710.1371/journal.pcbi.1008157 ↗
16. 10.18632/oncotarget.1967210.18632/oncotarget.19672 ↗
17. Gao YQ, Zhu KH, Xv YC, et al. Preliminary study on enhancing chemosensitivity of subcutaneous xenograft of breast cancer in nude mice with polymeric human umbilical cord hemoglobin oxygen carrier. Chinese J Blood Transf. 2022;35(05):475–479.
18. Dong DC, Gao YQ, Wang H, et al. Preliminary experiment on enhancing the therapeutic effect of lenvatinib on subcutaneous xenograft of liver cancer in nude mice using aggregated human umbilical cord blood hemoglobin oxygen carriers. Chinese J Blood Transf. 2021;34(5):456–460.
19. 10.1371/journal.pone.019127510.1371/journal.pone.0191275 ↗
20. 10.1016/j.canlet.2011.07.00310.1016/j.canlet.2011.07.003 ↗
21. 10.1667/RR1984.110.1667/RR1984.1 ↗
22. 10.1021/acsnano.7b0473710.1021/acsnano.7b04737 ↗
23. 10.1038/nrc239710.1038/nrc2397 ↗
24. 10.1038/nrclinonc.2012.17110.1038/nrclinonc.2012.171 ↗
25. 10.18632/oncotarget.2777610.18632/oncotarget.27776 ↗
26. 10.1038/nrc145610.1038/nrc1456 ↗
27. 10.1002/advs.20210412510.1002/advs.202104125 ↗
28. 10.1007/s10555-007-9055-110.1007/s10555-007-9055-1 ↗
29. 10.1039/c6md00432f10.1039/c6md00432f ↗
30. 10.1186/1423-0127-19-10210.1186/1423-0127-19-102 ↗
31. 10.1038/onc.2014.7310.1038/onc.2014.73 ↗
32. 10.1016/j.breast.2014.02.00310.1016/j.breast.2014.02.003 ↗
33. Tiburcio PD, Choi H, Huang LE. Complex role of HIF in cancer: the known, the unknown, and the unexpected. Hypoxia. 2014;2:59–70.
34. 10.3892/ijo.2017.405710.3892/ijo.2017.4057 ↗
35. 10.1038/onc.2009.44110.1038/onc.2009.441 ↗
36. 10.1016/j.biomaterials.2018.08.00410.1016/j.biomaterials.2018.08.004 ↗
37. 10.1186/s13045-020-01030-w10.1186/s13045-020-01030-w ↗
38. 10.1016/j.canlet.2015.07.04410.1016/j.canlet.2015.07.044 ↗
39. 10.1016/j.jss.2007.12.77010.1016/j.jss.2007.12.770 ↗
40. 10.3390/cells1003061010.3390/cells10030610 ↗
41. 10.12968/hmed.2013.74.sup11.c16610.12968/hmed.2013.74.sup11.c166 ↗